| Not Yet Recruiting | A Study to Evaluate Pharmacokinetics, Safety, Tolerability, Immunogenicity and Pharmacodynamic Effects of Subc NCT07503340 | Hoffmann-La Roche | Phase 2 |
| Not Yet Recruiting | The HIt HArd and hiT Early in Multiple Sclerosis Trial NCT07517185 | Uppsala University | Phase 2 |
| Recruiting | The SetPoint System as a Pro-Remyelination Therapy for Relapsing-Remitting Multiple Sclerosis: A Pilot Study NCT06796504 | SetPoint Medical Corporation | N/A |
| Not Yet Recruiting | Cladribine Tablets as an Exit Therapy Strategy NCT06887426 | University Hospital, Strasbourg, France | — |
| Not Yet Recruiting | Administration of Fingolimod in Greek Patients With Multiple Sclerosis. NCT06949956 | Elpen Pharmaceutical Co. Inc. | — |
| Recruiting | Study to Evaluate the Usability and Value of Integrated Digital Solutions in Medical Care of Participants With NCT05949580 | Hoffmann-La Roche | — |
| Not Yet Recruiting | Productive Value of Sonographic Measurement of Optic Nerve in Transitional Multiple NCT06435962 | Assiut University | — |
| Active Not Recruiting | Serum Neurofilament Light in Multiple Sclerosis NCT06282081 | Dent Neuroscience Research Center | — |
| Recruiting | A Study to Compare Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of CT-P53 and Ocrevus in Patients W NCT05906992 | Celltrion | Phase 3 |
| Completed | Educational Kinesiology Program's Effect on Cognition, Manual Dexterity and Bimanual Coordination in MS Patien NCT07002151 | Cairo University | N/A |
| Unknown | Comparative Study of High-Efficacy Disease Modifying Treatment of Relapsing Multiple Sclerosis NCT06159712 | University of Aarhus | N/A |
| Completed | Study to Evaluate the Safety and Efficacy of PIPE-307 in Subjects With Relapsing-Remitting Multiple Sclerosis NCT06083753 | Contineum Therapeutics | Phase 2 |
| Terminated | Observational Study of Persistence on Bafiertam Treatment in Routine Clinical Practice NCT05978531 | Banner Life Sciences LLC | — |
| Recruiting | RItuximab Versus Ocrelizumab in Relapsing-remitting Multiple Sclerosis. NCT05758831 | Rennes University Hospital | Phase 3 |
| Completed | A Study to Assess the Effectiveness and Safety of Mayzent in Chinese Patients With Relapsing Forms of Multiple NCT06395909 | Novartis | — |
| Active Not Recruiting | Functional Outcomes From Diets in Multiple Sclerosis NCT05327322 | University of Alabama at Birmingham | N/A |
| Active Not Recruiting | WEBCAMS: Walking Exercise for Brain and Cognition in Adults With Multiple Sclerosis NCT05755061 | Kessler Foundation | Phase 1 |
| Completed | Study to Assess Changes in Immunoglobulins in Patients With Relapsing Multiple Sclerosis Treated With Anti-CD2 NCT06526000 | Novartis | — |
| Unknown | Implementation of a Novel Functional Eye-Tracking Biomarker for Multiple Sclerosis NCT05277740 | McGill University | — |
| Enrolling By Invitation | Visual Processing Speed and Objective Analysis of Ocular Movements in Multiple Sclerosis NCT05706220 | Instituto Universitario de Oftalmobiología Aplicada (Institute of Applied Ophthalmobiology) - IOBA | — |
| Active Not Recruiting | A Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison With Fingolimod in Children and Adolescen NCT05123703 | Hoffmann-La Roche | Phase 3 |
| Active Not Recruiting | A Multicenter Study of Continued Current Therapy vs Transition to Ofatumumab After Neurofilament (NfL) Elevati NCT05090371 | Novartis Pharmaceuticals | Phase 4 |
| Completed | Lesion Load and Location in Relation to Cognition, Fatigue and Physical Disability in RRMS NCT05604092 | Assiut University | — |
| Unknown | Multiple Sclerosis Outcome Determination Evaluating Real Differences After TimE NCT05446285 | NHS Greater Glasgow and Clyde | — |
| Active Not Recruiting | Reduced Oligodendrocyte-specific Cytotoxicity and Ofatumumab Treatment NCT05171972 | University of Southern California | — |
| Completed | Safety and Effectiveness of Generic Fingolimod (Sphingomod®, Hikma) in Patients With Relapsing-Remitting Multi NCT05423769 | Hikma Pharmaceuticals LLC | — |
| Completed | Exercise on Contactin-1 and Contactin-2 Level in Persons With Multiple Sclerosis NCT05351411 | Firat University | — |
| Recruiting | Understanding the 'Durable Effect' Concept of B-cell Modulating Therapies NCT06586177 | Heinrich-Heine University, Duesseldorf | — |
| Terminated | Ocrelizumab or Alemtuzumab Compared With Autologous Hematopoietic Stem Cell Transplantation in Multiple Sclero NCT04971005 | Universitätsklinikum Hamburg-Eppendorf | Phase 2 |
| Completed | Effectiveness of Cladribine Tablets in Participants With Highly-active Relapsing Multiple Sclerosis (CAMELOT-M NCT04997148 | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | — |
| Completed | MS Relapses During COVID-19 Pandemic NCT04858763 | Nottingham University Hospitals NHS Trust | — |
| Completed | Special Drug-use Surveillance for Kesimpta for s.c. Injection 20 mg Pen NCT04940065 | Novartis Pharmaceuticals | — |
| Withdrawn | Observational Study in Patients With Relapsing-Remitting Multiple Sclerosis Switched to Bafiertam® From Dimeth NCT04925778 | Banner Life Sciences LLC | — |
| Completed | Bioequivalence Study of Bafiertam 190 mg and Vumerity® 462 mg Delayed-Release Capsules in Fasting Healthy Subj NCT05181215 | Banner Life Sciences LLC | Phase 1 |
| Active Not Recruiting | Non-inferiority Study of Ocrelizumab and Rituximab in Active Multiple Sclerosis NCT04688788 | Rigshospitalet, Denmark | Phase 3 |
| Recruiting | Rituximab and Ocrelizumab in Serum With Multiple Sclerosis NCT06663111 | Haukeland University Hospital | — |
| Unknown | A Phase 2 Study of Orelabrutinib in Patients With Relapsing-Remitting Multiple Sclerosis NCT04711148 | Beijing InnoCare Pharma Tech Co., Ltd. | Phase 2 |
| Completed | Effectiveness and Safety of Generic Delayed-Release Dimethyl Fumarate (Sclera® or Marovarex ®, Hikma) in Routi NCT04468165 | Hikma Pharmaceuticals LLC | — |
| Completed | Identification of Retinal Perivascular Inflammation in Patients With Multiple Sclerosis Using Adaptive Optics NCT04289909 | Institut National de la Santé Et de la Recherche Médicale, France | N/A |
| Recruiting | Investigation of Subclinical Markers of Multiple Sclerosis NCT04604041 | University of Split, School of Medicine | — |
| Completed | Assessment of ANK-700 in Patients With Relapsing Remitting Multiple Sclerosis NCT04602390 | Anokion SA | Phase 1 |
| Active Not Recruiting | Ocrelizumab VErsus Rituximab Off-Label at the Onset of Relapsing MS Disease NCT04578639 | Haukeland University Hospital | Phase 3 |
| Recruiting | SIZOMUS Safety of Ixazomib Targeting Plasma Cells in Multiple Sclerosis NCT03783416 | Queen Mary University of London | Phase 1 |
| Active Not Recruiting | Clinically Isolated Syndrome and Relapsing-Remitting Multiple Sclerosis NCT04009005 | Terry L. Wahls | N/A |
| Unknown | Personalized Extended Interval Dosing of Natalizumab in Relapsing Remitting Multiple Sclerosis NCT04225312 | Amsterdam UMC, location VUmc | Phase 4 |
| Active Not Recruiting | Dendritic Cells Therapy Combined With Immunomodulatory Treatment in Multiple Sclerosis NCT04530318 | Judit Pich | Phase 2 |
| Recruiting | Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS) NCT04047628 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 3 |
| Completed | Serum Neurofilaments and GFAP in Atypical Multiple Sclerosis NCT04201470 | University Hospital, Montpellier | N/A |
| Terminated | Study of Evobrutinib in Participants With RMS NCT04032171 | EMD Serono Research & Development Institute, Inc. | Phase 3 |
| Terminated | Study of Evobrutinib in Participants With Relapsing Multiple Sclerosis (RMS) NCT04032158 | EMD Serono Research & Development Institute, Inc. | Phase 3 |
| Completed | PET with [18F]Flumazenil As an Index of Neurodegeneration in MS NCT03825601 | Institut National de la Santé Et de la Recherche Médicale, France | N/A |
| Terminated | Nanocrystalline Gold to Treat Remyelination Failure in Chronic Optic Neuropathy In Multiple Sclerosis NCT03536559 | Clene Nanomedicine | Phase 2 |
| Terminated | Fecal Microbiota Transplantation (FMT) of FMP30 in Relapsing-Remitting Multiple Sclerosis NCT03594487 | Jeffrey Gelfand | Phase 1 |
| Completed | Utilization of the Ketogenic Diet in Patient With Relapsing Remitting MS NCT03718247 | University of Virginia | — |
| Completed | Upper Extremity Function in Multiple Sclerosis Patients With Advanced Disability Treated With Ocrevus NCT03562975 | University of South Florida | — |
| Completed | Correlation Between Daily Physical Activity and Disability, Fatigue, Cognition and Quality of Life in MS Patie NCT04115930 | University of Eastern Finland | — |
| Completed | Melatonin in Patients With Multiple Sclerosis (MS). NCT03498131 | Providence Health & Services | EARLY_Phase 1 |
| Completed | Mechanistic Studies of Teriflunomide in RRMS NCT03464448 | University of Michigan | — |
| Completed | Intermittent Fasting in Multiple Sclerosis NCT03539094 | Washington University School of Medicine | N/A |
| Completed | Behavior and Activity Monitoring in MS NCT03244696 | Ohio State University | N/A |
| Completed | Neuropsychological Management of Multiple Sclerosis: Benefits of a Computerised Semi-autonomous At-home Cognit NCT03471338 | University Hospital, Caen | N/A |
| Completed | Retrospective Study to Determine Effect of Rebif and Tecfidera on Infections and Lymphocytes NCT03284970 | EMD Serono Research & Development Institute, Inc. | — |
| Completed | COMparison Between All immunoTherapies for Multiple Sclerosis. NCT03193866 | Karolinska Institutet | — |
| Completed | Evaluating the Efficacy and Safety of Transitioning Patients From Natalizumab to Ocrelizumab NCT03157830 | Providence Health & Services | — |
| Completed | An Extension of the TG1101-RMS201 Trial NCT03381170 | TG Therapeutics, Inc. | Phase 2 |
| Completed | Behavior Cognitive Therapy on Fatigue Impact in MS Patients NCT03758820 | Réseau Sep Idf Ouest | N/A |
| Completed | Comparison of Oral Molecules Preventing Relapses in Multiple Sclerosis NCT03302442 | Nantes University Hospital | — |
| Terminated | Fingolimod Versus Dimethyl-fumarate in Multiple Sclerosis NCT03345940 | Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta | Phase 4 |
| Completed | A Tolerability Study of ALKS 8700 in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) EVOLVE-MS-2 NCT03093324 | Biogen | Phase 3 |
| Completed | Effects of Vitamin K on Redness Associated With Injection Site Reactions in Participants Treated With Plegridy NCT03091569 | Biogen | Phase 4 |
| Terminated | A Study of Efficacy and Safety of M2951 in Participants With Relapsing Multiple Sclerosis NCT02975349 | EMD Serono Research & Development Institute, Inc. | Phase 2 |
| Completed | Evaluate Safety/Tolerability in Portuguese Participants With RRMS Transitioning From Current Therapy NCT03177083 | Biogen | Phase 4 |
| Completed | Comparative Bioavailability of BAFIERTAM™ (Monomethyl Fumarate) and Tecfidera® (Dimethyl Fumarate) in Healthy NCT04570670 | Banner Life Sciences LLC | Phase 1 |
| Unknown | Clinical Importance of Glucose Regulation in Relapsing MS NCT03004079 | University of Virginia | — |
| Completed | Biological Activity and Safety of Low Dose IL2 in Relapsing Remitting Multiple Sclerosis NCT02424396 | Assistance Publique - Hôpitaux de Paris | Phase 2 |
| Completed | Follow up Study of Patients on Fingolimod Who Were Enrolled in the Original Biobank Study (CFTY720DDE01) NCT02720107 | Novartis Pharmaceuticals | Phase 4 |
| Withdrawn | Placebo-Controlled Study of the Efficacy and Safety of BG00012 in Pediatric Subjects With Relapsing-Remitting NCT02428218 | Biogen | Phase 3 |
| Completed | Patient Real-world Clinical, Neurological, Tolerability, and Safety Outcomes for Tecfidera® and Rebif® NCT02823951 | IMS HEALTH GmbH & Co. OHG | — |
| Terminated | Teriflunomide's Therapeutic Mechanisms of Action in Patients With Relapsing Remitting Multiple Sclerosis. NCT02833714 | University of North Carolina, Chapel Hill | — |
| Completed | Clinical Disease Activity With Long Term Natalizumab Treatment NCT02677077 | Biogen | — |
| Completed | A Pilot Study of Intermittent Calorie Restriction in Multiple Sclerosis NCT02647502 | Johns Hopkins University | N/A |
| Completed | Teriflunomide Observational Effectiveness Study NCT02490982 | Centre hospitalier de l'Université de Montréal (CHUM) | — |
| Completed | Guided Versus Non-guided Pelvic Floor Exercises for Urinary Incontinence in Relapsing-Remitting Multiple Scler NCT03000647 | Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz | N/A |
| Completed | Mitochondrial Dysfunction and Disease Progression NCT02549703 | Icahn School of Medicine at Mount Sinai | — |
| Withdrawn | Study to Explore the Onset of Efficacy on Magnetic Resonance Disease Activity of BG00012 (Dimethyl Fumarate) i NCT02472938 | Biogen | Phase 4 |
| Completed | High Dose Oral Versus Intramuscular Vitamin D3 Supplementation In Multiple Sclerosis Patients NCT02696590 | Isfahan University of Medical Sciences | N/A |
| Withdrawn | Study to Evaluate Fatigue in Participants With Relapsing Remitting Multiple Sclerosis When Treated With Dimeth NCT02090348 | Biogen | Phase 4 |
| Completed | Autologous Mesenchymal Stromal Cells for Multiple Sclerosis NCT02495766 | Banc de Sang i Teixits | Phase 1 / Phase 2 |
| Terminated | Effectiveness of DMF (Dimethyl Fumarate) and Its Impact on PROs (Patient Reported Outcomes) in Treatment-Naive NCT02323269 | Biogen | — |
| Completed | Fingolimod Effect on Cytokine and Chemokine Levels NCT02373098 | Novartis Pharmaceuticals | Phase 4 |
| Terminated | Efficacy and Safety of Vatelizumab in Patients Who Completed Treatment in Study DRI13839 NCT02306811 | Genzyme, a Sanofi Company | Phase 2 |
| Completed | Phase IIIB-IV Long-Term Follow-up Study for Patients Who Participated in CAMMS03409 NCT02255656 | Genzyme, a Sanofi Company | Phase 4 |
| Unknown | Immune- and miRNA-response to Recombinant Interferon Beta in Healthy Volunteers and Patients With Relapsing Re NCT02364986 | PD Dr. Marcus Müller | Phase 1 |
| Terminated | Impact of Natalizumab Versus Fingolimod in Relapsing-Remitting Multiple Sclerosis (RRMS) Participants NCT02342704 | Biogen | Phase 4 |
| Completed | PROFILE - Evaluation of QoL and PRO Outcomes in Patients Taking Fingolimod NCT02335892 | Novartis Pharmaceuticals | — |
| Completed | Comparative Oral Bioavailability Study of MT-1303 NCT02310048 | Tanabe Pharma Corporation | Phase 1 |
| Completed | Management Of The Infusion-Associated Reactions In RRMS Patients Treated With LEMTRADA NCT02205489 | Genzyme, a Sanofi Company | Phase 4 |
| Terminated | Improving Cognitive Aptitudes With tDCS in Patients With Multiple Sclerosis NCT02266121 | University Hospital of Mont-Godinne | N/A |
| Completed | Mass Balance Study of MT-1303 NCT02293967 | Tanabe Pharma Corporation | Phase 1 |
| Terminated | Efficacy and Safety of Vatelizumab in Patients With Relapsing-Remitting Multiple Sclerosis NCT02222948 | Genzyme, a Sanofi Company | Phase 2 |
| Completed | Phase 3 Efficacy and Safety Study of BG00012 in Pediatric Subjects With Relapsing-remitting Multiple Sclerosis NCT02283853 | Biogen | Phase 3 |
| Terminated | Pilot Study to Assess Dimethyl Fumarate Related GI Symptom Mitigation NCT02217982 | Rocky Mountain MS Research Group, LLC | Phase 4 |
| Completed | Real-world Outcomes on Tecfidera (BG00012, Dimethyl Fumarate) Post-Tysabri (BG00002, Natalizumab) NCT02159573 | Biogen | — |
| Completed | Gastrointestinal Tolerability Study Of Dimethyl Fumarate In Participants With Relapsing-Remitting Multiple Scl NCT02125604 | Biogen | Phase 4 |
| Completed | Tolerability of Acthar for the Treatment of Multiple Sclerosis in Relapses (TAMS) NCT02258217 | OhioHealth | N/A |
| Completed | Phase 4 Study of Effect of Aspirin on Flushing in Dimethyl Fumarate-Treated Participants With Relapsing-Remitt NCT02090413 | Biogen | Phase 4 |
| Unknown | Effects of a 12-week Respiratory Muscles Training Program in Persons With Relapsing- Remitting Multiple Sclero NCT02104492 | University of Malaga | N/A |
| Unknown | Study to Assess Immune Function and MRI Disease Activity in RRMS Patients When Switching From Natalizumab to G NCT02325440 | University Hospital Muenster | Phase 4 |
| Withdrawn | A Study to Evaluate 2 Doses Of Oral Administration Of Laquinimod Compared to Interferon ß-1a Administered by I NCT01975298 | Teva Branded Pharmaceutical Products R&D, Inc. | Phase 3 |
| Completed | Development of a Talk Therapy Protocol to Help Patients Make Treatment Decisions in MS NCT02010554 | University of Missouri, Kansas City | N/A |
| Completed | Study of Tysabri in Early Relapsing Remitting Multiple Sclerosis Participants NCT04832399 | Biogen | — |
| Completed | A Study Evaluating the Effectiveness of Tecfidera (Dimethyl Fumarate) on Multiple Sclerosis (MS) Disease Activ NCT01930708 | Biogen | Phase 4 |
| Terminated | Efficacy, Safety, and Tolerability of Plovamer Acetate (Pathway 1) NCT01963611 | EMD Serono | Phase 2 |
| Completed | Efficacy and Safety of BCD-063 and Copaxone-Teva in Patients With Relapsing-Remitting Multiple Sclerosis NCT02753088 | Biocad | Phase 3 |
| Terminated | Monitoring Natural Killer Cells in Multiple Sclerosis Patients Treated With Fingolimod NCT01790269 | Charite University, Berlin, Germany | — |
| Completed | Pilot Study to Assess Disease Stability in a Natalizumab to Dimethyl Fumarate Crossover Design NCT01945359 | Rocky Mountain MS Research Group, LLC | — |
| Completed | Extension Study of MT-1303 NCT01890655 | Tanabe Pharma Corporation | Phase 2 |
| Completed | A Safety and Efficacy Study of Oral Prolonged-Release Fampridine (BIIB041) in Japanese Participants With Multi NCT01917019 | Biogen | Phase 3 |
| Completed | PK and PD Study of Natalizumab in Pediatric Subjects With RRMS NCT01884935 | Biogen | Phase 1 |
| Withdrawn | Effect of an Individualized Patient Support Program on Treatment Satisfaction in Fingolimod-treated Patients W NCT01709812 | Novartis Pharmaceuticals | Phase 4 |
| Completed | Tolerability and Quality of Life Study in Participants Who Switched to Avonex Pen NCT02076841 | Biogen | — |
| Completed | Proof of Concept Study of RHB-104 as Add-On Therapy to Interferon Beta-1a in Relapsing Remitting Multiple Scle NCT01717664 | RedHill Biopharma Limited | Phase 2 |
| Completed | Safety and Tolerability of Glatiramer Acetate NCT01874145 | Teva Branded Pharmaceutical Products R&D, Inc. | Phase 3 |
| Completed | Safety Study of Olesoxime in Patients With Stable Relapsing Remitting Multiple Sclerosis Treated With Interfer NCT01808885 | Hoffmann-La Roche | Phase 1 |
| Completed | Raltegravir (Isentress) Pilot Study in Relapsing Multiple Sclerosis NCT01767701 | Queen Mary University of London | Phase 2 |
| Completed | Assessment of Attentional and Executive Disorders in Multiple Sclerosis Using Techniques of Virtual Reality NCT01805336 | University Hospital, Caen | N/A |
| Completed | An Efficacy and Safety Study of BG00012 (Dimethyl Fumarate) in Asian Subjects With Relapsing Remitting Multipl NCT01838668 | Biogen | Phase 3 |
| Terminated | Long-Term Extension Study in Participants With Multiple Sclerosis Who Have Completed Study 205MS301 (NCT010644 NCT01797965 | Biogen | Phase 3 |
| Completed | Development of a Motivational Intervention to Improve Treatment Adherence in MS NCT01925690 | University of Missouri, Kansas City | N/A |
| Terminated | Long-term Effect of Fingolimod on Circulating Immunocompetent Mononuclear Cells in Patients With Multiple Scle NCT01755871 | Heinrich-Heine University, Duesseldorf | Phase 4 |
| Completed | Dose-finding Study of MT-1303 NCT01742052 | Tanabe Pharma Corporation | Phase 2 |
| Terminated | Canadian Multicenter Observational Study of Tysabri in Early Relapsing Remitting Multiple Sclerosis Participan NCT01706107 | Biogen | — |
| Terminated | Natalizumab De-escalation to Interferon-beta-1b in Patients With Relapsing-remitting Multiple Sclerosis NCT01701856 | Claudio Gobbi | Phase 4 |
| Completed | A Pilot Trial to Test the Feasibility of Prolonged Fasting and Ketogenic Diet in Relapsing-remitting Multiple NCT01538355 | Charite University, Berlin, Germany | N/A |
| Completed | Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients Wit NCT01623596 | Novartis Pharmaceuticals | Phase 4 |
| Completed | Safety and Efficacy of Natalizumab (BG00002, Tysabri®) in Russian Participants With Relapsing Remitting Multip NCT02142205 | Biogen | Phase 4 |
| Completed | Disease Control in RRMS Transferring Treatment From Natalizumab to Fingolimod NCT02277964 | University Hospital, Basel, Switzerland | — |
| Completed | Vitamin D Supplementation in Multiple Sclerosis NCT01490502 | Johns Hopkins University | Phase 3 |
| Terminated | An Efficacy, Safety and Tolerability Study of Glatiramer Acetate (GA) 20 mg/0.5 ml New Formulation Administere NCT01578785 | Teva Branded Pharmaceutical Products R&D, Inc. | Phase 3 |
| Completed | Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JC Virus Antibody Negat NCT01485003 | Biogen | — |
| Completed | A Study of MSDx Complex 1 as a Marker for Therapy Response in Multiple Sclerosis NCT01541618 | MSDx, Inc. | — |
| Completed | Evaluation of Patient Reported Outcomes in RRMS Patients Candidates for MS Therapy Change and Transitioned to NCT01534182 | Novartis Pharmaceuticals | Phase 4 |
| Completed | Efficacy of Fingolimod in de Novo Patients Versus Fingolimod in Patients Previously Treated With a First Line NCT01498887 | Novartis Pharmaceuticals | Phase 4 |
| Completed | Ireland Natalizumab (TYSABRI) Observational Program NCT01943526 | Biogen | — |
| Terminated | Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depr NCT01436643 | Novartis Pharmaceuticals | Phase 4 |
| Completed | An Open-Label Immunogenicity and Pharmacokinetics Study of Daclizumab High Yield Process Prefilled Syringe in NCT01462318 | Biogen | Phase 3 |
| Completed | Effects of Electromechanical Gait Trainer in Patients With Multiple Sclerosis NCT01564511 | Universita di Verona | N/A |
| Unknown | Phase 3 Study to Evaluate Efficacy and Safety of NU100 in Patients With Relapsing Remitting Multiple Sclerosis NCT01464905 | Nuron Biotech Inc. | Phase 3 |
| Unknown | Estriol Treatment in Multiple Sclerosis (MS): Effect on Cognition NCT01466114 | University of California, Los Angeles | Phase 2 |
| Completed | Glatiramer Acetate for Multiple Sclerosis With Autoimmune Comorbidities NCT01456416 | University of Southern California | — |
| Completed | Safety, Tolerability And Mechanism Of Action Of Boswellic Acids (BA) In Multiple Sclerosis (SABA) NCT01450124 | Universitätsklinikum Hamburg-Eppendorf | Phase 2 |
| Completed | Exploratory Study of the Safety, Tolerability and Efficacy of Multiple Regimens of Natalizumab in Adult Partic NCT01405820 | Biogen | Phase 2 |
| Completed | A Phase IIa Study of NT-KO-003 for Multiple Sclerosis NCT01428726 | Neurotec Pharma | Phase 2 |
| Completed | Patients With Relapse Remitting Multiple Sclerosis (RRMS): Candidates for MS Therapy Change NCT01317004 | Novartis Pharmaceuticals | Phase 4 |
| Unknown | Impact of Vitamin A on Gene Expression, in Multiple Sclerosis Patient NCT01407211 | Tehran University of Medical Sciences | Phase 4 |
| Completed | Advanced MRI Measures of Repair in Alemtuzumab Treated Patients NCT01307332 | University of British Columbia | Phase 3 |
| Completed | Autologous Mesenchymal Stem Cell (MSC) Transplantation in MS NCT00813969 | The Cleveland Clinic | Phase 1 |
| Completed | Biomarker Study After Initiation of Treatment With Fingolimod (FTY720) in Patients With Relapsing-remitting Mu NCT01310166 | Novartis Pharmaceuticals | Phase 4 |
| Completed | Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclero NCT01285401 | Merck KGaA, Darmstadt, Germany | Phase 2 |
| Withdrawn | High Dose Cyclophosphamide Followed by Glatiramer Acetate in the Treatment of Relapsing Remitting Multiple Scl NCT00939549 | Johns Hopkins University | Phase 2 |
| Completed | Safety Study of BIIB033 in Subjects With Multiple Sclerosis NCT01244139 | Biogen | Phase 1 |
| Completed | Extension Study to Evaluate Safety and Efficacy of Natalizumab in Japanese Participants With Relapsing-Remitti NCT01416155 | Biogen | Phase 2 |
| Completed | Long-term Safety, Tolerability and Efficacy of BAF312 Given Orally in Patients With Relapsing-remitting Multip NCT01185821 | Novartis Pharmaceuticals | Phase 2 |
| Withdrawn | Using Optical Coherence Tomography (OCT) to Evaluate the Efficacy and Safety of PEGylated Interferon Beta-1a ( NCT01337427 | Johns Hopkins University | Phase 3 |
| Completed | A Study in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tole NCT01067521 | Teva Branded Pharmaceutical Products R&D, Inc. | Phase 3 |
| Completed | BG00012 Phase 2 Combination Study in Participants With Multiple Sclerosis NCT01156311 | Biogen | Phase 2 |
| Completed | Natalizumab De-escalation With Interferon Beta-1b NCT01144052 | Claudio Gobbi | Phase 4 |
| Completed | Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon β 1a in Participants With Rel NCT01064401 | Biogen | Phase 3 |
| Completed | Efficacy of Fish Oil in Multiple Sclerosis NCT01842191 | Coordinación de Investigación en Salud, Mexico | Phase 4 |
| Completed | Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) (BIIB019) in Participants Who H NCT01051349 | Biogen | Phase 2 |
| Terminated | Study Evaluating Rebif, Copaxone, and Tysabri for Active Multiple Sclerosis NCT01058005 | Biogen | Phase 3 |
| Completed | ATX-MS-1467 in Patients With Relapsing Forms of Multiple Sclerosis NCT01097668 | Apitope Technology (Bristol) Ltd. | Phase 1 |
| Completed | Treatment Interruption of Natalizumab NCT01071083 | Biogen | Phase 2 |
| Unknown | Impact of Vitamin A on RAR Gene Expression in Multiple Sclerosis NCT01705457 | Tehran University of Medical Sciences | Phase 4 |
| Unknown | Impact of Vitamin A on Multiple Sclerosis (MS) NCT01417273 | Tehran University of Medical Sciences | Phase 4 |
| Completed | Patient Research Cohort: Rapidly Evolving Multiple Sclerosis NCT01044576 | Imperial College London | — |
| Completed | POC-MD MRI-based Trial in Relapsing-remitting Multiple Scler NCT01051817 | Novartis Pharmaceuticals | Phase 2 |
| Completed | Sensori-motor Integration Training in Multiple Sclerosis NCT01040117 | Universita di Verona | EARLY_Phase 1 |
| Terminated | A Study of Orally Administered BGC20-0134 (Structured Lipid) in Patients With Relapsing Remitting Multiple Scl NCT01037907 | Boston Scientific Corporation | Phase 2 |
| Completed | Impact of Vitamin A Supplementation on Immune System in Multiple Sclerosis Patients NCT01225289 | Tehran University of Medical Sciences | Phase 4 |
| Completed | Safety of New Formulation of Glatiramer Acetate NCT00947752 | Teva Branded Pharmaceutical Products R&D, Inc. | Phase 3 |
| Unknown | The Neuroprotective Effect of Lamotrigine and Interferon Beta 1a in Patients With Relapsing-Remitting Multiple NCT00917839 | Cantonal Hospital of St. Gallen | Phase 2 |
| Completed | Injection Management With Betaferon: Influence on Adherence, Patients Satisfaction and Health Related Outcomes NCT00902135 | Bayer | — |
| Completed | A Study of Participants With Relapsing-Remitting Multiple Sclerosis (RRMS) NCT00882999 | Eli Lilly and Company | Phase 2 |
| Completed | Safety, Tolerability, Efficacy and Optimal Dose Finding Study of BAF312 in Patients With Relapsing-remitting M NCT00879658 | Novartis Pharmaceuticals | Phase 2 |
| Completed | Effects of Tysabri (BG00002) Over 12 Months on MS Related Fatigue in Participants With RRMS NCT00884481 | Biogen | — |
| Completed | A Proof of Concept Study to Evaluate the Effectiveness of Tysabri in Relapsing Remitting Multiple Sclerosis (R NCT00818038 | Biogen | — |
| Unknown | Comparison of Campath and Rebif Treatment on Cognition in Multiple Sclerosis (MS) NCT00914758 | Washington Neuropsychology Research Group | — |
| Completed | A 24-Hour Pharmacokinetic Determination of BG00012 After Single-Day Oral Administration in Subjects With MS NCT00837785 | Biogen | Phase 1 |
| Completed | BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS) NCT00835770 | Biogen | Phase 3 |
| Completed | Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) in Participants With Multiple S NCT00870740 | Biogen | Phase 2 |
| Withdrawn | A Proof-of-Concept Study to Correlate Retinal Nerve Fiber Layer Changes in Patients With Multiple Sclerosis Tr NCT00771043 | Biogen | Phase 4 |
| Terminated | Exploratory Study on the Timing of Multiple Sclerosis (MS) Symptoms NCT00919217 | University of Louisville | — |
| Completed | Helminth-induced Immunomodulation Therapy (HINT) in Relapsing-remitting Multiple Sclerosis NCT00645749 | University of Wisconsin, Madison | Phase 1 |
| Withdrawn | Simvastatin as an add-on Treatment to Copaxone for the Treatment of Relapsing Multiple Sclerosis NCT00429442 | Anna Tsakiri | Phase 3 |
| Completed | CLARITY Extension Study NCT00641537 | EMD Serono Research & Development Institute, Inc. | Phase 3 |
| Completed | Safety and Efficacy Study of Daclizumab High Yield Process (DAC HYP) to Treat Relapsing-Remitting Multiple Scl NCT00390221 | Biogen | Phase 2 |
| Completed | fMRI Study of Treatment Recommendations Comparing Recently Diagnosed Multiple Sclerosis (MS) Patients to Contr NCT00391352 | Waukesha Memorial Hospital | — |
| Terminated | Flupirtine as Oral Treatment in Multiple Sclerosis NCT00623415 | Charite University, Berlin, Germany | Phase 2 |
| Completed | Safety Study of Natalizumab to Treat Multiple Sclerosis (MS) NCT00559702 | Biogen | Phase 1 |
| Completed | Sunphenon Epigallocatechin-gallate (EGCg) in Relapsing-remitting Multiple Sclerosis (SuniMS Study) NCT00525668 | Charite University, Berlin, Germany | Phase 1 / Phase 2 |
| Completed | Tysabri Observational Program NCT00493298 | Biogen | — |
| Completed | Efficacy and Safety Study of Oral BG00012 With Active Reference in Relapsing-Remitting Multiple Sclerosis NCT00451451 | Biogen | Phase 3 |
| Terminated | How Side Effects of Avonex Are Affected by Gradually Increasing to Full Dose vs Starting at Full Dose NCT00574041 | Biogen | Phase 4 |
| Completed | A Combination Trial of Copaxone Plus Estriol in Relapsing Remitting Multiple Sclerosis (RRMS) NCT00451204 | University of California, Los Angeles | Phase 2 |
| Completed | Efficacy, Safety and Tolerability of Atorvastatin 40 mg in Patients With Relapsing-remitting Multiple Sclerosi NCT01111656 | Insel Gruppe AG, University Hospital Bern | Phase 2 |
| Completed | Efficacy and Safety of Oral BG00012 in Relapsing-Remitting Multiple Sclerosis NCT00420212 | Biogen | Phase 3 |
| Completed | Eszopiclone for Improving Sleep in Multiple Sclerosis (MS) NCT00594087 | University of Vermont | N/A |
| Completed | A Study for Patients With Relapsing Remitting Multiple Sclerosis NCT00869986 | Eli Lilly and Company | Phase 2 / Phase 3 |
| Terminated | An fMRI Study of Treatment Optimization Comparing Two Disease Modifying Therapies Used to Treat Relapsing Remi NCT00398528 | Neurognostics | — |
| Completed | Clinical Trial Comparing Treatment of Relapsing-Remitting Multiple Sclerosis (RR-MS) With Two Doses of Glatira NCT00337779 | Teva Branded Pharmaceutical Products R&D, Inc. | Phase 3 |
| Completed | High-Dose Immunosuppression and Autologous Transplantation for Multiple Sclerosis (HALT MS) Study NCT00288626 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2 |
| Completed | Autologous T Cell Vaccine (TCV) for Multiple Sclerosis NCT00245622 | Opexa Therapeutics, Inc. | Phase 2 |
| Completed | GER-009-06-AVX Early Therapy in Multiple Sclerosis NCT00492570 | Biogen | — |
| Completed | Safety Study in Relapsing-remitting Multiple Sclerosis (RRMS) Patients Receiving Betaferon or Rebif NCT00317941 | Bayer | Phase 4 |
| Terminated | Natalizumab (Tysabri) Re-Initiation of Dosing NCT00297232 | Biogen | Phase 3 |
| Completed | BHT-3009 Immunotherapy in Relapsing Remitting Multiple Sclerosis NCT00382629 | Bayhill Therapeutics | Phase 2 |
| Completed | Efficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis NCT00289978 | Novartis | Phase 3 |
| Terminated | An Extension Study of LAQ/5062 Exploring the Long Term Safety, Tolerability and Clinical Effect Parameters Dur NCT00745615 | Teva Pharmaceutical Industries, Ltd. | Phase 2 |
| Unknown | A Safety Study of Combination Treatment With Avonex and Zocor in Relapsing Remitting Multiple Sclerosis NCT00242268 | Alabama Neurology Associates, PC | Phase 3 |
| Completed | A Study to Evaluate the Long Term Safety and Effectiveness of Novantrone Therapy Followed by Copaxone Treatmen NCT00203086 | Teva Branded Pharmaceutical Products R&D, Inc. | — |
| Completed | An Observational Study of Multiple Sclerosis (MS) Patients Starting or Restarting Baseline Treatment With Inte NCT01142518 | Merck KGaA, Darmstadt, Germany | — |
| Completed | An Observational Study Evaluating Therapy Optimisation Using High-frequency and High-dosage Administration of NCT01142453 | Merck KGaA, Darmstadt, Germany | — |
| Completed | Simvastatin in Relapsing Remitting Multiple Sclerosis (RRMS) Patients Using Avonex Compared to Placebo NCT00668343 | Tehran University of Medical Sciences | Phase 3 |
| Completed | A Study to Evaluate the Effectiveness, Tolerability and Safety of Laquinimod NCT00349193 | Teva Branded Pharmaceutical Products R&D, Inc. | Phase 2 |
| Terminated | Assessment Study of Steroid Effect in Relapsing Multiple Sclerosis Subjects Treated With Glatiramer Acetate NCT00203047 | Teva Branded Pharmaceutical Products R&D, Inc. | Phase 4 |
| Completed | Combination Therapy in Patients With Relapsing-Remitting Multiple Sclerosis (MS)CombiRx NCT00211887 | Fred Lublin | Phase 3 |
| Completed | A Postmarketing Surveillance (PMS) Study to Evaluate the Extent to Which Patient Compliance is Influenced by U NCT01142492 | Merck KGaA, Darmstadt, Germany | — |
| Completed | Safety and Efficacy of Pravastatin in Relapsing-remitting Multiple Sclerosis NCT00200655 | Nantes University Hospital | Phase 3 |
| Completed | Omega-3 Fatty Acid Treatment in Multiple Sclerosis NCT00360906 | Haukeland University Hospital | Phase 2 / Phase 3 |
| Withdrawn | Implementation Study of Treatment Optimization Recommendations on Relapsing-Remitting Multiple Sclerosis (RR M NCT00101959 | EMD Serono | Phase 4 |
| Completed | A fMRI(Functional Magnetic Resonance Imaging) Research Study to Learn More About Multiple Sclerosis and Indivi NCT00315367 | Neurognostics | Phase 4 |
| Terminated | A Study to Assess the Effects of MK0812 on Disease Activity in Patients With Relapsing-Remitting Multiple Scle NCT00239655 | Merck Sharp & Dohme LLC | Phase 2 |
| Terminated | Randomized Study Designed to Look at Disease Progression Using 2 Currently FDA Approved Drugs for the Treatmen NCT00202995 | Teva Branded Pharmaceutical Products R&D, Inc. | Phase 4 |
| Completed | Study To Evaluate The Immunogenicity And Safety Of r-hIFN Beta-1a (Rebif®) Using Clone 484-39 In Multiple Scle NCT00367484 | Merck KGaA, Darmstadt, Germany | Phase 4 |
| Completed | Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis NCT00078338 | EMD Serono | Phase 4 |
| Completed | Safety/Effectiveness of Adding Monthly Dexamethasone to Weekly Avonex for MS NCT00232193 | Providence Multiple Sclerosis Center | — |
| Completed | Is IFN-beta Treatment in MS Useful After a Washout Period in Patients With Neutralizing Antibodies to Interfer NCT00493116 | Biogen | Phase 4 |
| Completed | Atorvastatin in Relapsing-Remitting Multiple Sclerosis NCT00616187 | Charite University, Berlin, Germany | Phase 2 |
| Completed | A Study to Evaluate the Safety and Effectiveness of Novantrone Therapy Followed by Copaxone for Multiple Scler NCT00203073 | Teva Branded Pharmaceutical Products R&D, Inc. | Phase 2 |
| Unknown | Evaluation of Efficiency of Ritalin in Multiple Sclerosis (MS) Patients NCT00220493 | Sheba Medical Center | Phase 1 |
| Completed | Investigating if Interferon-Beta Can be Used in Patients With MS After They Have Developed Neutralizing Antibo NCT00492466 | Biogen | Phase 4 |
| Completed | Avonex (Interferon-beta-1a) and Avonex Plus Methylprednisolone for the Treatment of Relapsing-remitting MS NCT00168766 | Biogen | Phase 4 |
| Unknown | Combination Therapy (Provigil + Avonex) to Treat Cognitive Problems in MS NCT00210301 | Institute for Clinical Research | N/A |
| Completed | Does Quality of Life Improve in Multiple Sclerosis Patients Treated With Interferon Beta-1a? NCT00534261 | Biogen | Phase 4 |
| Terminated | Evaluation of a New Therapeutic Strategy in Early and Active Relapsing-Remitting Multiple Sclerosis NCT00219908 | Rennes University Hospital | Phase 2 |
| Completed | Vitamin D Pilot Study in Patients With Multiple Sclerosis NCT01257958 | University of Wisconsin, Madison | Phase 1 |
| Completed | Glatiramer Acetate (Copaxone®) Study to Follow Participants From the First Original Study for Safety and Effec NCT00203021 | Teva Branded Pharmaceutical Products R&D, Inc. | Phase 4 |
| Withdrawn | Proof of Concept Study Evaluating RNS60 in the Treatment of Relapsing Remitting Multiple Sclerosis NCT01714089 | Revalesio Corporation | Phase 2 |
| Completed | A Phase 1 Study to Explore the Cardiac Pharmacodynamics of MT-1303 NCT02193217 | Tanabe Pharma Corporation | Phase 1 |